Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

Viridian Therapeutics, Inc.

Biona offers a variety of organic food products, including bakery items, snacks, meals, sauces, and cooking ingredients, focused on health and sustainability. The company is self-described as making it easier for consumers to shop sustainably.

Biona

Viridian Therapeutics leverages expertise in antibody discovery and engineering to develop optimized treatments for rare autoimmune conditions, self-described.

Metric
Company Name	Viridian Therapeutics, Inc.	Biona
Symbol	VRDN
MSH ID	COM:VIRIDIANTHERAPEUTICS	UK:CO:BIONA
Market	STOCKS	PRIVATE
Sector	Healthcare	Consumer Goods
Industry	Biotechnology	Food & Beverage
Country	US	GB
Stage
Employee Count	94
Website	viridiantherapeutics.com	biona.co.uk
LinkedIn		bionaorganic
Founders

Metric
Market Cap	783.10M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	314K
Revenue (LTM)
Revenue (NTM)
Gross Profit	-1.01M
EBITDA	-235.37M
Operating Income	-254.45M
Net Income	-237.73M
EPS	-5.31
Diluted EPS	-5.31
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-2.58
Operating Profit Margin	-810.35
EBITDA Margin	-749.57
Net Profit Margin	-756.78
Return on Equity	-0.50
Return on Assets	-0.35
Return on Capital Employed	-0.39

COM:VIRIDIANTHERAPEUTICS

Viridian Therapeutics

Last Close

19.62

22/11 21:00

Market Cap

783.10M

Beta: -

Volume Today

858.39K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-3.84
P/B Ratio	2.88
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	6.62K
EV Multiple	-3.55

Metric
Days Sales Outstanding	107.29
Days Payables Outstanding
Days Inventory Outstanding	0.00
Operating Cycle	129.27
Cash Conversion Cycle	-168.03
Asset Turnover	0.00

Metric
Operating Cash Flow	-184.17M
Free Cash Flow	-185.07M
Cash Flow to Debt	-5.98
Operating Cash Flow/Sales	-424.33
Free Cash Flow Yield	-0.18

Metric
Cash & Equivalents	102.83M
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization	0.05
Debt to Assets	0.06
Current Ratio	13.93
Quick Ratio	23.99

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	133.72
R&D to Revenue	462.61
SG&A to Revenue	207.09